[Skip to Navigation]
September 1991

Psychiatric Effects of Selegiline

Author Affiliations

Department of Neurology University of Colorado Health Sciences Center 4200 E Ninth Ave Denver, CO 80262

Arch Neurol. 1991;48(9):902. doi:10.1001/archneur.1991.00530210028017

To the Editor.  —The exciting news that selegiline (deprenyl, Eldepryl) may retard the progression of early Parkinson's disease,1,2 accompanied by the observation that few significant adverse effects were observed in these studies, has led physicians to treat many of their Parkinson's disease patients with this drug. This report concerns adverse psychiatric effects seen in my referral population of patients with Parkinson's disease. Over the last year, we have started selegiline therapy in approximately 60 patients, almost all of whom were both on multiple other antiparkinsonian medications and known to me for some time prior to this treatment. I have not included adverse effects that could be ameliorated by reduction of the dose of carbidopa/levodopa.Apparent adverse effects in the younger population were most common in physically small patients, especially women. Five otherwise healthy women in their 40s and 50s developed adverse effects, although only two of these had a

Add or change institution